TrialLeukemia & lymphoma2019

Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.

Milos D Miljkovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.